title: A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb.
abstract: The aim of this study was to assess whether isolated limb perfusion can be performed safely and whether it offers improved disease-free survival for patients with limb malignant melanoma. Between August 1983 and July 1993, 103 patients (78 female, 25 male) with recurrent limb melanoma were treated by isolated limb perfusion (ILP) in Glasgow, U.K. The mean age of the patients was 62 years; 95 had leg recurrence, 8 had arm recurrence. The mean time from original diagnosis to ILP was 48 months (range 1-290). 102 iliac, 5 femoral, 7 popliteal and 8 axillary perfusions were performed. All patients had stage II (local recurrence within 3 cm of primary site) or stage III (regional metastases; tissues excluding nodes, nodes or combination) disease according to the MD Anderson Cancer Centre Staging System. At a mean follow-up of 30.7 months, 68 patients had died of recurrent disease (mean time to death 22.5 months). The 2 and 5 year survival of the group was 50 and 26%, respectively and disease-free survival was 23 and 12%, respectively. At first perfusion, 76% of patients showed complete response and 23% showed partial response. With repeat perfusion, 47% showed complete response and 53% had partial response. In conclusion, ILP is safe and has an acceptable morbidity. It achieves highly satisfactory local disease control but long-term survival is the exception.
authors.affiliation: Department of Vascular Surgery, Gartnavel General Hospital, Scotland, U.K.
authors.forename: M K
authors.initials: MK
authors.lastname: Lingam
authors.forename: D S
authors.initials: DS
authors.lastname: Byrne
authors.forename: T
authors.initials: T
authors.lastname: Aitchison
authors.forename: R M
authors.initials: RM
authors.lastname: MacKie
authors.forename: A J
authors.initials: AJ
authors.lastname: McKay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects; D018572:Disease-Free Survival; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D012737:Sex Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D015996:Survival Rate
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan